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ABSTRACT
In this study, we demonstrate that receptor-
associated protein 80 (RAP80) interacts with estro-
gen receptor alpha (ERa) in an agonist-dependent
manner. The interaction is specific for ERa as ERb
and several other nuclear receptors tested did not
interact with RAP80. Interaction between RAP80
and ERa was supported by mammalian two-hybrid,
GST pull-down, and co-immunoprecipitation ana-
lyses. The hinge/ligand-binding domain of ERa
is sufficient for interaction with RAP80. RAP80
overexpression reduces ERa polyubiquitination,
increases the level of ERa protein, and enhances
ERa-mediated transactivation. Knockdown of endo-
genous RAP80 expression by small-interfering RNA
(siRNA) reduced ERa protein level and the E2-
dependent induction of pS2. In this study, we also
demonstrate that RAP80 contains two functional
ubiquitin-interaction motifs (UIMs) that are able to
bind ubiquitin and to direct monoubiquitination of
RAP80. Deletion of these UIMs does not affect the
ability of RAP80 to interact with ERa, but eliminates
the effects of RAP80 on ERa polyubiquitination,
the level of ERa protein, and ERa-mediated
transcription. These data indicate that the UIMs in
RAP80 are critical for the function of RAP80. Our
study identifies ERa as a new RAP80-interacting
protein and suggests that RAP80 may be an
important modulator of ERa activity.
INTRODUCTION
Estrogens are important for a number of physiological
processes that include various reproductive functions
and bone metabolism (1–3). The biological actions of
estrogens are primarily mediated by two high-aﬃnity
nuclear receptors, estrogen receptor a and b (ERa and
ERb) (3,4). In the classical model of nuclear receptor
action, ER binding of estrogen releases the receptor from
inactive complexes containing heat-shock proteins and
immunophilins, followed by dimerization, and binding
of ER homodimers to estrogen-response elements (EREs)
in the regulatory regions of target genes. Agonist binding
induces a conformational change including a reposition-
ing of helix 12 which represents the ligand-inducible
activation function AF-2 (3–7). This allows recruitment
of co-activator complexes that cause decompactation of
chromatin through their histone acetylase activity and
transcriptional activation of target genes. In addition
to co-activators, a large number of other proteins
that interact with ERa and modify its transcriptional
activity have been identiﬁed (8–12). Moreover, various
posttranslational modiﬁcations, including phosphoryla-
tion, sumoylation and ubiquitination, have been reported
to modulate ERa activity (9,13–16). Polyubiquitination
and degradation of ERa and other nuclear receptors
by the ubiquitin–proteasome system is important for
regulating nuclear receptor levels and their transcriptional
activities (14,16–21). Several components of the ubiquitin-
proteasome degradation system, such as PSMC5
(SUG/TRIP1) (22), RSP5/RPF1 (23), UBCH7 (24) and
CHIP (16), have been reported to interact with a number
of nuclear receptors, including ERa. Recently, sumoyla-
tion has been identiﬁed as another mechanism that
regulates the transcriptional activity of ERa and was
shown to involve UBC9, PIAS1 and PIAS3 (9,25).
However, our knowledge about the mechanisms by
which ubiquitination and sumoylation regulate nuclear
receptor level and activity is still far from complete.
We recently described the identiﬁcation of a novel
protein, referred to as receptor-associated protein
80 (RAP80) or ubiquitin interaction motif containing
1 (UIMC1) as approved by the HUGO Gene
Nomenclature Committee (26). RAP80 is an acidic
nuclear protein of 719 amino acids that contains two
Cys-X2-Cys-X11-His-X3-Cys zinc ﬁnger-like motifs near
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tissues, most abundantly in testis. RAP80 was shown
to interact with the retinoid-related testis-associated
receptor (RTR), also known as germ cell nuclear factor
(GCNF) or NR6A1 (26–29). The objective of the current
study was to determine the potential role of RAP80
in modulating the activity of other nuclear receptors.
Yeast two-hybrid analysis demonstrated that RAP80
interacted with ERa, but not with ERb or several other
nuclear receptors. This interaction required the presence
of an agonist, such as estrogen, while antagonists did
not induce the interaction. RAP80 was found to contain
two putative ubiquitin-interacting motifs (UIM
RAP80)
at its amino terminus. UIMs consist of a short-sequence
motif of about 20 residues reported to direct (multi)-
monoubiquitination of proteins that contain this motif.
In addition, UIMs have been shown to bind ubiquitin and
ubiquitin-like motifs (30–33). UIMs were ﬁrst identiﬁed in
the S5a subunit of the 19S proteasome complex (34).
UIMs have subsequently been found in a variety
of proteins with roles in endocytosis, DNA repair,
(de)ubiquitination, replication and transcription (32,33).
In this study, we show that the UIMs in RAP80 promote
monoubiquitination and are able to bind ubiquitin and,
therefore, are functional UIM sequences. Moreover, we
demonstrate that RAP80 reduces the polyubiquitination
of ERa and increases the level of ERa protein and
ERa-mediated transcription. The UIM
RAP80 is essential
for these eﬀects of RAP80 on ERa. Our study identiﬁes
RAP80 as a UIM-containing and ERa-interacting protein
and provides evidence for a role of RAP80 as a modulator
of ERa-dependent transcriptional activation.
MATERIALS AND METHODS
Plasmids
The yeast and mammalian two-hybrid vectors pGBKT7,
pGBT9, pGADT7, pM, pVP16, and the retroviral
vector pLXIN were purchased from BD Biosciences
(Palo Alto, CA). The reporter plasmid pFR-Luc, contain-
ing 5 copies of the GAL4 upstream-activating sequence
(UAS), referred to as (UAS)5-Luc, was obtained
from Stratagene (La Jolla, CA). pcDNA3.1 and
pcDNA3.1( )Myc-His were purchased from Invitrogen
(Carlsbad, CA) and pCMV–3 FLAG-7.1 from Sigma
(St. Louis, MO). PhRL–SV40 encoding the Renilla
luciferase was obtained from Promega (Madison, WI).
To create pGADT7–RAP80N135, the region encoding
aa 135 to the carboxyl terminus, was ampliﬁed by PCR
and the ampliﬁed product was inserted into the EcoRI and
BamHI sites of pGADT7. RAP80N129 and full-length
ERa were inserted in-frame into EcoRI and BamHI sites
of pM and pVP16, respectively, for use in mammalian
two-hybrid assays. The ERE–CAT reporter, in which the
CAT reporter is under the control of the natural ERE
from the VitA2 promoter, was a gift from Dr Christina
Teng (NIEHS). The ERa expression vector pERa and the
(ERE)3-Luc reporter were kindly provided by Dr Donald
McDonnell (Duke University). The pcDNA3.1–RAP80
was generated by inserting full-length RAP80 into the
expression vector pcDNA3.1. pLXIN–3 FLAG–RAP80
was constructed by inserting 3 FLAG–RAP80 into the
vector pLXIN. pcDNA3.1–ERa–Myc-His plasmids con-
taining either full-length ERa,E R aN180, ERaN248
or ERaC248 were generated by inserting the corre-
sponding coding regions, obtained by PCR ampliﬁcation,
into the EcoRI and BamHI sites of pcDNA3.1( )Myc-
His. The pLXIN–3 FLAG–RAP80 mutants K90R,
K112R and K90,112R were generated using a
Quickchange site-directed mutagenesis kit (Stratagene).
The pLXIN–3 FLAG–RAP80 mutants UIM1,
UIM2 and UIM1,2, in which the regions encoding
the UIM1, UIM2 or both were deleted, were generated by
PCR ampliﬁcation. The regions up- and down-stream
from the UIMs were ﬁrst ampliﬁed by PCR, then ligated
at the introduced XhoI sites, and subsequently inserted
into the EcoRI and BamHI sites of pLXIN–3 FLAG.
The pLXIN–3 FLAG–RAP80 deletion mutants, encod-
ing the regions between aa 1-582, 1-524, 1-504, 1-404,
1-304, 1-204,1-122 and 1-78 were generated by PCR
ampliﬁcation and then inserted into the EcoRI and
BamHI sites of pLXIN–3 FLAG. The pLXIN–
3 FLAG–RAP80C122 mutants A88S, A113S and
A88,113S were generated with a Quickchange site-directed
mutagenesis kit. PEGFP–UIM1,2 was constructed by
inserting the UIMs of RAP80 into EcoRI and BamHI sites
of pEGFP-C1. pGEX–UIM1,2 was constructed by
inserting the UIMs of RAP80 into BamHI and
EcoRI sites of pGEX–5x-3. pCMV–HA–Ub, encoding
HA–ubiquitin, and pcDNA3–HA–Nedd8 were gifts
from Dr Yue Xiong (University of North Carolina,
Chapel Hill, NC).
Yeast two-hybrid screening
Brieﬂy, Saccharomyces cerevisiae Y187 (MATa) were
transformed with pGADT7–RAP80 (FL) or
pGADT7N129 plasmid DNA. pGBT9 plasmid DNAs,
encoding the ligand-binding domain or the full-length
coding region of various nuclear receptors, were provided
by Dr Michael Albers (PheneX-Pharmaceuticals,
Heidelberg). pGBT9 plasmids were transformed into S.
cerevisiae strain AH109(MATa). After mating, double
transformants were selected in minimal Synthetic Dropout
medium (SD-Trp-Leu). The transformants were then
grown in SD-Leu-Trp-His containing 50mM 4-methylum-
belliferyl a-d-galactopyranoside (4-MuX) (Sigma) in the
presence or absence of corresponding ligand. The mixture
was incubated for 48h and ﬂuorescence measured
(excitation 360nm, emission 465nm wavelength).
pGBKT7–p53, encoding GAL4 DNA-binding domain
(DBD)–p53, and pGADT7–TD1-1, encoding the GAL4-
activation domain fused to the SV40 large T antigen, were
used as a positive control in yeast two-hybrid analysis.
GST pull-down assay
E. coli BL21 cells (Stratagene) transformed with pGEX or
pGEX–RAP80N110 plasmid DNA were grown at 378C
to mid-log phase. Synthesis of GST or GST fusion protein
was then induced by the addition of isopropylthiogalacto-
pyranoside (IPTG; 0.5mM ﬁnal concentration) at 378C.
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in BugBuster protein extraction reagent (Novagen,
Madison, WI) and processed according to the manufac-
turer’s protocol. Cellular extracts were then centrifuged at
15000 g, and the supernatants containing the soluble
GST proteins were collected. Equal amounts of GST–
RAP80N110 protein or GST protein were incubated
with glutathione-Sepharose 4B beads and washed
in phosphate-buﬀered saline. [
35S]-methionine-labeled
ERa and its deletion mutants were generated using the
TNT Quick Coupled Transcription/Translation system
(Promega). The GST- and GST–RAP80N110-bound
beads were then incubated with [
35S]-methionine-labeled
ERa in 0.5ml binding buﬀer (20mM Tris-HCl, pH7.6,
100mM KCl, 0.05% Nonidet P-40, 0.1mM EDTA, 10%
glycerol, 1mM PMSF) in the presence or absence of 1mM
E2. After 1h incubation at room temperature, beads were
washed ﬁve times in binding buﬀer and boiled in 15ml
2 SDS-PAGE loading buﬀer. Solubilized proteins were
separated by 4–12% SDS-PAGE and the radiolabeled
proteins visualized by autoradiography. To analyze
ubiquitin binding, 500ng of a mixture of polyubiquitin
chains (Ub2-7) (Biomol, Plymouth Meeting, PA) were
incubated with puriﬁed GST or GST–UIM
RAP80 protein.
GST protein complexes were isolated with glutathione-
Sepharose 4B beads and examined by western blot
analysis with an anti-ubiquitin antibody (Covance).
Co-immunoprecipitation assay
HeLa cells were transiently transfected with pLXIN–
3 FLAG–RAP80 (full-length or mutant) and
pcDNA3.1–ERa–Myc-His or pERa, as indicated, using
Fugene 6 transfection reagent (Roche, Indianapolis, IN).
Forty-eight hours after transfection, cells were harvested
and lysed for 1h in NP40 lysis buﬀer (150mM NaCl,
0.5% NP40, 50mM NaF, 50mM Tris-HCl, pH8.0)
containing protease inhibitor cocktails I and II (Sigma).
The cell lysates were centrifuged at 14000 g at 48C
for 10min. The supernatants were then incubated with
anti-FLAG M2 aﬃnity resin overnight to isolate FLAG–
RAP80 protein complexes. The resin was washed three
times with lysis buﬀer. The bound protein complexes were
then solubilized in sample buﬀer and analyzed by western
blot analysis using anti-ERa (Santa Cruz) and anti-FLAG
M2 (Sigma) antibodies.
Ubiquitination assay
HeLa cells were transiently transfected with pcDNA3.1–
ERa–Myc-His, pLXIN–3 FLAG–RAP80 or pLXIN–
3 FLAG–RAP80UIM1,2 and pCMV–HA–Ub.
Forty-four hours after transfection, cells were treated
with 25mM MG132 or ethanol for 4h. Cells were then
harvested and lysed for 1h in modiﬁed RIPA buﬀer
(50mM Tris/HCl (pH7.8), 150mM NaCl2, 5mM EDTA,
15mM MgCl2, 0.5% NP-40, 0.3% Triton X-100, 0.5%
sodium deoxycholate, 1mM dithiothreitol, 10mM
N-ethylmaleimide and 0.1% SDS) containing protease
inhibitor cocktails. The cell lysates were centrifuged at
14000 g at 48C for 10min. The supernatants were
incubated with anti-ERa antibody and protein-G agarose
(Sigma) overnight to pull down ERa protein complexes.
The agarose was then washed three times with lysis buﬀer.
The bound proteins were solubilized in sample buﬀer and
analyzed by western blot analysis using anti-HA (Sigma)
and anti-ERa antibodies.
Reporter geneassay
CHO and MCF-7 cells were maintained in phenol red-free
F12 or RPMI1640 supplemented with 10% charcoal-
stripped fetal bovine serum (Sigma). Cells were transfected
using Fugene 6 transfection reagent with the reporter
plasmids pERE–CAT or (ERE)3-Luc, RAP80 and ERa
expression vectors, and the internal standard b-galactosidase
expression vector or phRL–SV40, as indicated. Five hours
after transfection, the medium was replaced and 16h later
agonists or antagonists (Sigma) were added. After an
additional 24h incubation, cells were harvested in passive
lysis buﬀer (Promega) and the level of luciferase or CAT
protein measured using the Dual-Luciferase Reporter
Assay System (Promega) or CAT-ELISA kit (Roche). All
analyses were performed in triplicate.
RAP80knockdown
MCF-7 cells were transfected with scrambled or RAP80
SMARTpool siRNA reagent (Dharmacon) according
to the manufacturer’s instructions. Cells were maintained
in phenol red-free RPMI 1640 supplemented with 10%
charcoal-stripped fetal bovine serum (Sigma) for 48h,
followed by a 24h treatment with E2. Cells were then
collected, protein lysates prepared and examined by
western blot analysis using antibodies against RAP80
(Bethyl, TX), pS2 (Santa Cruz), ERa and actin.
RESULTS
Identification of ERaas anew RAP80-interacting protein
Earlier, we demonstrated that the nuclear protein RAP80
interacts with and modulates the activity of the nuclear
orphan receptor RTR/GCNF (26). To determine whether
RAP80 was able to interact with other nuclear receptors,
we performed yeast two-hybrid analysis using RAP80 as
prey and several full-length nuclear receptors or their ligand-
binding domains as bait. The yeast strain AH109(MATa)
was transformed with pGBT9 plasmids encoding various
nuclear receptors and then mated with Y187(MATa)
containing pGADT7–RAP80N110. The potential inter-
actions between RAP80 and nuclear receptors were
analyzed in the presence or absence of corresponding
ligand. This analysis identiﬁed ERa as a new RAP80-
binding partner and demonstrated that this interaction
required the presence of the ERa agonist 17b-estradiol (E2)
(Figure 1A). In the presence of E2, RAP80 was able to
interact with both full-length ERa and the ligand-binding
domain of ERa (ERa(LBD)) suggesting that the amino
terminus, including the DNA-binding domain (DBD), is not
an absolute requirement for the interaction. RAP80 did not
show any substantial interaction with the vitamin D
receptor (VDR), androgen receptor (AR), liver X receptor
a (LXRa), retinoid X receptor a (RXRa), peroxisome
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(RARg) either in the presence or absence of corresponding
ligand. The RORg receptor, which appears to be
constitutively active, also did not interact with RAP80.
As shown in Figure 1B, the interaction of RAP80 with
full-length ERa was dependent on the concentration
of E2. A concentration as low as 0.2 nM E2 was able
to induce the interaction between RAP80 and ERa.
The EC50 was calculated to be 1.9 nM E2. RAP80
did not interact with full-length ERb (Figure 1B) or
ERb(LBD) (not shown) either in the presence or absence
of E2. These observations indicate that the interaction
of RAP80 with nuclear receptors is highly selective for
ERa and is ligand dependent.
Mammalian two-hybrid analysis
The interaction of RAP80 with ERa was conﬁrmed
by mammalian two-hybrid analysis. CHO cells were
co-transfected with (UAS)5-Luc reporter, pM–RAP80
and increasing amounts of pVP16–ERa plasmid DNA.
As shown in Figure 2A, expression of GAL4(DBD)–
RAP80 alone did not enhance transcriptional activa-
tion of the (UAS)5-Luc reporter. Co-expression of
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Figure 1. RAP80 interacts selectively with ERa. The interaction of
RAP80 with diﬀerent nuclear receptors was analyzed by yeast two-
hybrid analysis as described in Materials and Methods. RAP80
was used as bait and several full-length (FL) nuclear receptors or
their LBD were used as prey. (A) The interaction of RAP80
with diﬀerent nuclear receptors was analyzed in the presence (þ)o r
absence ( ) of corresponding agonist. The following agonists were
used: 1,25-dihydroxyvitamin D3 (100nM) for VDR; dihydrotestoster-
one (100nM) for AR; T0901317 (1mM) for LXRa; GW845 (100nM)
for PPARg;1 7 b-estradiol (100nM) for ERa(FL) and ERa(LBD); the
RXR-panagonist SR11217 (1mM); retinoic acid (1mM) for RARg.
(B) Interaction of ERa(FL) and ERb(FL) with RAP80 as a function of
the estradiol concentration.
A
B
Figure 2. Analysis of the interaction between RAP80 and ERa by
mammalian two-hybrid analysis. (A) CHO cells were co-transfected
with (UAS)5-Luc reporter, pM–RAP80, increasing amounts of pVP16–
ERa and pcDNA3.1–RAP80 as indicated. Sixteen hours later cells were
treated with 100 nM E2 or vehicle. Cells were assayed for reporter
activity 24h after the addition of E2. The relative Luc activity was
calculated and plotted. (B) Agonists but not antagonists induce
interaction between RAP80 and ERa. CHO cells were co-transfected
with pM–RAP80N130, pVP16–ERa and pS5–CAT reporter. Cells
were treated with diﬀerent agonists or antagonists (1mM) as indicated.
Cells were assayed for the reporter activity 24h after transfection.
Ligands used: E2, 17b-estradiol; Tam, tamoxifen; ICI, ICI 182,780; E3,
estriol; ZZ-dienestrol; DES, diethylstilbestrol.
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increased reporter activity, while addition of E2 greatly
induced this reporter activity. Co-transfection with the
expression plasmid pcDNA3.1–RAP80 totally abrogated
this induction due to competition of RAP80 with
GAL4(DBD)–RAP80N129 for ERa binding. These
observations support our conclusion that RAP80 interacts
with ERa in an E2-dependent manner.
We next compared the eﬀect of several ER agonists
and antagonists on the interaction of RAP80 with ERa.
CHO cells were co-transfected with pM–RAP80N129,
pVP16–ERa, and the pS5–CAT reporter plasmid contain-
ing ﬁve tandem GAL4-binding elements. Sixteen hours
later cells were treated with various (ant)agonists. As
shown in Figure 2B, all agonists tested, E2, estriol (E3)
and diethylstilbestrol (DES), induced the interaction of
ERa with RAP80. The weak agonist ZZ-dienestrol also
induced the interaction; however, treatment with the
antagonists tamoxifen (Tam) and ICI 182,780 (ICI) did
not promote the interaction between ERa and RAP80.
These results indicate that the interaction of RAP80 with
ERa is dependent on the presence of an ERa agonist.
Thus, only RAP80 interacts with a transcriptionally active
form of ERa.
Co-immunoprecipitation and GST pull-down analysis
To investigate this interaction further, we performed
co-immunoprecipitation analysis. HeLa cells were co-
transfected with pcDNA3.1–ERa–Myc-His and pLXIN–
3 FLAG–RAP80 expression plasmids, treated with
100nM E2 or ethanol (vehicle) before cells were harvested
and cell lysates prepared. Part of the cell lysates was
used directly for western blot analysis while the remaining
was incubated with anti-FLAG M2 aﬃnity resin to
isolate FLAG–RAP80 protein complexes. As shown in
Figure 3A, ERa was immunoprecipitated with FLAG–
RAP80 only when E2 was present. These observations are
in agreement with the conclusion that RAP80 and ERa
interact with each other in an agonist-dependent manner.
We next examined whether E2 was able to induce the
interaction between endogenous ERa and RAP80. MCF-7
cells were treated with or without E2 or ICI 182,780
for 3h before nuclear lysates were prepared. RAP80
protein complexes were then immunoprecipitated using an
anti-RAP80 antibody and the immunoprecipitated
RAP80 protein complexes were examined by western
blot analysis with an anti-ERa antibody. Figure 3B shows
that endogenous ERa and RAP80 interact with each
other. ERa was found in complex with RAP80 only in
the presence of E2. The association between ERa and
RAP80 was conﬁrmed by analysis of ERa protein
complexes immunoprecipitated with an anti-ERa
antibody (Figure 3C).
We next examined the interaction of RAP80 with
ERa by in vitro pull-down analysis using puriﬁed
GST–RAP80N110 fusion protein and [
35S]-labeled full-
length ERa. This analysis showed little interaction
between RAP80 and ERa in the absence of E2
(Figure 3D); however, signiﬁcant binding of ERa to
RAP80 was observed in the presence of E2. GST alone did
not bind ERa either in the presence or absence of E2.
To examine which region of ERa was required for
this interaction with RAP80, GST pull-down analysis
was performed with three ERa deletion mutants,
ERaN248, ERaN180 and ERaC248. As shown in
Figure 3E, in the presence of E2, RAP80 was able to bind
ERaN180 and ERaN248, but not ERaC248. These
results demonstrate that the amino terminus of ERa
is unable to bind RAP80 and that the LBD of ERa
is required and suﬃcient for interaction with RAP80.
In addition, these observations suggest that RAP80
physically interacts with ERa.
Effectof various deletions inRAP80 on its interaction
withERa
RAP80 contains two putative zinc ﬁnger-like motifs at its
carboxyl terminus, between aa 505 and 582. To determine
which region of RAP80 was important for its interaction
with ERa, we constructed a series of carboxyl-terminal
deletion mutants (Figure 4A) and examined their ability
to interact with ERa by co-immunoprecipitation analysis
(Figure 4B). The results demonstrated that carboxyl-
terminal deletions up to aa 504 had little eﬀect on the
ability of RAP80 to bind ERa, while RAP80C404 was
still able to co-immunoprecipitate ERa but less eﬃciently.
In contrast, RAP80C304 and likewise the more severe
deletion mutants RAP80C204 and RAP80C122 were
unable to interact with ERa. These observations indicate
that the region of RAP80 between aa 304 and 404
is critical for the interaction with ERa and that the
carboxyl-terminal zinc ﬁnger-like motifs are not required.
Although several amino-terminal deletions of RAP80
were constructed, none of amino-truncated proteins were
expressed in cells. This might be due to improper folding
of these mutants and their rapid degradation by the
proteasome system.
Effectof RAP80on ERa-mediated transcriptional activation
To examine the functional signiﬁcance of the RAP80–ERa
interaction, we determined whether RAP80 had any
eﬀect on the transcriptional activity of endogenous ERa.
MCF–7 cells were co-transfected with an (ERE)3-Luc
reporter and diﬀerent amounts of RAP80 expression
vector, and then treated with or without E2. As
demonstrated in Figure 5, RAP80 increased E2-induced
transcriptional activation by endogenous ERa. In contrast
to full-length RAP80, the deletion mutant RAP80C204,
which does not interact with ERa, had no eﬀect on ERa
transcriptional activity. An increase in ERa-mediated
transactivation was also observed in CHO cells transfected
with an ERE–CAT reporter plasmid, and ERa and/or
RAP80 expression plasmids (Figure S1A). E2 induced
reporter activity in cells transfected with the ERa expres-
sion vector, this activation was further increased by 3-fold
in cells co-transfected with the RAP80 expression vector.
To determine whether this increase was speciﬁc for
ERa-mediated transactivation or whether RAP80 aﬀected
the general transcriptional machinery, the eﬀect of
RAP80 on RORE-dependent transcriptional activation by
RORg, a nuclear receptor that does not interact with
Nucleic Acids Research, 2007, Vol. 35, No. 5 1677RAP80, was examined. Figure S1B shows that RAP80 had
no eﬀect on RORg-mediated transactivation.
RAP80expression affects ERaprotein levels
To examine whether RAP80 had any eﬀect on the level of
ERa protein, HeLa cells were transfected with the
expression vector pERa in the presence or absence of
pLXIN–3 FLAG–RAP80. As shown in Figure 6A, the
level of ERa protein was very low in HeLa cells
transfected with pERa only. In cells co-expressing
RAP80 and ERa, the level of total ERa protein
was greatly enhanced but only in cells treated with
E2. Similar results were obtained with ERa protein
co-immunoprecipitated by FLAG–RAP80. These obser-
vations suggest that expression of RAP80 enhances the
A
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Figure 3. Analysis of the interaction between RAP80 and ERa by co-immunoprecipitation and GST pull-down assays. (A) Co-immunoprecipitation
analysis. HeLa cells were transfected with pcDNA3.1–ERa–Myc-His and pLXIN–3 FLAG–RAP80 expression plasmids (1g each) and treated
with 100nM E2 or ethanol as indicated. After 24h, cell lysates were prepared and FLAG–RAP80 protein complexes were isolated using anti-FLAG
M2 agarose aﬃnity resin. Proteins in the total cellular lysates and immunoprecipitated (IP) proteins were examined by western blot analysis with
anti-FLAG M2 and anti-ERa antibodies. Western blot analysis of IP proteins is shown in the left panel and that of 10% of cell lysates in the right
panel. (B) Interaction between endogenous RAP80 and ERa. MCF-7 cells were grown in phenol-red-free medium with 10% charcoal-stripped serum
for 2 days and subsequently treated with or without 100 nM E2 or 1M ICI 182,780. After 3h incubation, cells were collected and nuclear lysates
prepared. RAP80 protein complexes were immunoprecipitated with an anti-RAP80 antibody and examined by western blot analysis with anti-RAP80
and anti-ERa antibodies. Lower panel shows input ERa. (C) MCF-7 cells were grown and treated with 100nM E2 as described under (B) before cell
lysates were prepared. One part of the lysates was analyzed by western blot analysis using an anti-RAP80 antibody (input RAP80). The remaining
lysates were subjected to immunoprecipitation with an anti-ERa antibody or control rabbit IgG (Santa Cruz). The immunoprecipitated ERa protein
complexes were then examined by western analysis with anti-RAP80 and anti-ERa antibodies. (D) GST pull-down assay. GST and GST–
RAP80110 fusion protein were bound to glutathione-Sepharose 4B beads and then incubated with [
35S]-methionine radiolabeled ERa in the
presence or absence of 1M E2. After 1h incubation, beads were washed extensively and bound proteins solubilized. Radiolabeled proteins were
analyzed by PAGE and visualized by autoradiography. Lane 1: 20% input of radiolabeled ERa. (E) GST pull-down assays were carried out as under
(C) using three ERa deletion mutants, ERaN248, ERaN180 and ERaC248.
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on the presence of an agonist. This enhancement in
ERa protein was not due to an increase in the levels
of ERa mRNA by RAP80 since levels of ERa mRNA
were very similar between MCF-7 and MCF-7–RAP80
(Figure S2).
We next examined the eﬀect of RAP80 knockdown by
RAP80 small-interfering RNA (siRNA) on endogenous
ERa protein in MCF-7 cells (Figure 6B). As reported
earlier (31,35), treatment with E2 reduced ERa levels
(compare lanes 1 and 2), this reduction was more
pronounced in cells in which RAP80 was down-regulated
(compare lanes 2 and 4). Little diﬀerence in ERa levels
was observed between untreated cells (lanes 1 and 3).
These data are in agreement with our conclusion that
RAP80 enhances the level of ERa protein. To analyze
the eﬀect of RAP80 knockdown on the transcriptional
activity of ERa, we examined its eﬀect on the induction of
the ERa target gene pS2. As shown in Figure 6B, the
induction of pS2 protein was signiﬁcantly less in cells
in which RAP80 expression was reduced in agreement
with our observations that increased RAP80 expression
enhances ERa activity.
Figure 5. Eﬀect of RAP80 on ERa-mediated transcriptional activation.
RAP80 increased transcriptional activation by endogeneous ERa.
MCF-7 cells were transfected with diﬀerent amounts of (ERE)3-Luc,
pLXIN–3 FLAG-RAP80 or pLXIN–3 FLAG–RAP80C204 as indi-
cated. Cells were treated with 100nM E2 or ethanol for 24h. Cells were
then collected and assayed for luciferase activity. RAP80 protein levels
were examined by western blot analysis with anti-FLAG M2 antibody
(lower panel).
A
B
Figure 4. Eﬀect of C-terminal deletions on the interaction of RAP80
with ERa. (A) Schematic of RAP80 deletion mutants. UIM and
ZF indicate the two ubiquitin-interacting and zinc ﬁngerlike
motifs, respectively. (B) HeLa cells were co-transfected with
pcDNA3.1–ERa–Myc-His and various pLXIN–3 FLAG–RAP80
plasmids as shown in (A). Cells were treated with E2 (0.1M) for
24h before cell lysates were prepared and FLAG–RAP80 protein
complexes isolated using anti-FLAG M2 agarose aﬃnity resin. Proteins
in the cellular lysates and immunoprecipitated (IP) proteins were
examined by western blot analysis with anti-FLAG M2 and anti-ERa
antibodies.
A
B
Figure 6. RAP80 expression increases the level of ERa protein.
(A) HeLa cells were transfected with 2g pERa and 1g pLXIN–
3 FLAG–RAP80 plasmid DNA. The cells were treated with 100nM
E2 or ethanol for 24h before cell lysates were prepared and FLAG–
RAP80 protein complexes isolated with anti-FLAG M2 aﬃnity resin.
The isolated complexes were examined by western blot analysis using
anti-FLAG M2 and anti-ERa antibodies. About 5% of the cell lysates
were used for direct Western blot analysis. (B) Eﬀect of RAP80
knockdown by RAP80 siRNA on the expression of ERa protein and
pS2 induction in MCF-7 cells. MCF-7 cells transfected with RAP80 or
scrambled siRNAs, were grown in phenol-red-free medium with 10%
charcoal-stripped serum for 2 days, and subsequently treated for 24h
with or without 100 nM E2. Cell lysates were prepared and examined
by western blot analysis with antibodies against ERa, pS2, RAP80, and
actin.
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A more extensive analysis of the RAP80 sequence showed
that, in addition to the two zinc ﬁnger motifs, RAP80 con-
tained two putative ubiquitin-interacting motifs (UIMs)
at its amino terminus of RAP80 between aa 79-96 and
104-121, respectively. These UIMs (UIM
RAP80) exhibit
highhomologywiththeconsensusUIM(Figure7A).UIMs
have been reported to bind ubiquitin and to direct
(multi)monoubiquitination of proteins that contain them
(31,35). Before investigating the role of UIM
RAP80 in the
interaction of RAP80 with ERa, we examined whether
these putative UIMs were functional by determining their
ability to bind ubiquitin. As shown in Figure 7B (lane 2),
UIM
RAP80 was able to bind Ub2-7. To determine whether
UIM
RAP80 could direct monoubiquitination of proteins
that contain this sequence, we analyzed the level of
ubiquitination of EGFP and a EGFP–UIM
RAP80 chimeric
fusion protein in HeLa cells transfected with or without
pCMV–HA–Ub,encodingHA-taggedubiquitin.Asshown
inFigure7C,EGFP–UIM
RAP80wasubiquitinatedinHeLa
cells only when HA–Ub was co-expressed. EGFP was not
ubiquitinated either in the presence or absence of HA–Ub
expression. These observations suggest that UIM
RAP80
is able to direct ubiquitination and, therefore, behaves as
a functional UIM.
Roleof UIMs on RAP80ubiquitination
UIM-containing proteins have been reported to become
(multi)monoubiquitinated (31,36). To determine whether
RAP80 was subject to ubiquitination, we examined the
ubiquitination of RAP80 in HEK293 cells treated with
and without the proteasome inhibitor MG132. Two major
ubiquitinated RAP80 proteins migrating at about 120 and
135kD and referred to as Ub–RAP80 and (Ub)2–RAP80,
were detected (Figure 8A). Previous studies have shown
that treatment with the proteasome inhibitor MG132
results in an accumulation of cellular polyubiquitinated
proteins that are otherwise rapidly degraded by the
proteasome system, whereas MG132 has little eﬀect on
monoubiquitinated proteins (21,31,32,37,38). Our data
show that MG132 treatment had little eﬀect on RAP80
ubiquitination (Figure 8A) suggesting that RAP80 itself
is not polyubiquitinated to a great extent or rapidly
degraded by the proteasome. Therefore, the two ubiqui-
tinated RAP80 proteins likely represent RAP80
conjugated to one or two monoubiquitins. The eﬀect of
Nedd8, a ubiquitin homolog, was analyzed to further
examine the speciﬁcity of the ubiquitination of RAP80.
These data showed that RAP80 was not neddylated
(not shown).
The UIMs in RAP80 contain two lysine residues
(K
90 and K
112) that are potential ubiquitination sites.
To determine whether these sites are important for the
multi-ubiquitination of RAP80, the eﬀect of point
mutations in these residues on RAP80 multi-ubiquitina-
tion was examined. None of the lysine mutants, K
90R,
K
112R, or the double mutant K
90,112R, aﬀected the degree
of ubiquitination of RAP80 suggesting that K
90 and K
112
are not substrates of monoubiquitination (Figure S3).
Further evidence for the role of UIM
RAP80 in the
monoubiquitination of RAP80 came from experiments
analyzing the ubiquitination of the amino terminus of
RAP80. RAP80C122, containing the amino terminus
including UIM
RAP80, was ubiquitinated whereas
RAP80C78, lacking the UIM
RAP80, was not suggesting
that the UIM is required for RAP80 ubiquitination
(Figure 8B). In the absence of exogenous HA–ubiquitin,
the anti-FLAG antibody recognized several bands
likely representing multi-ubiquitinated RAP80C122
conjugated with endogenous ubiquitin. No such bands
were observed with RAP80C78.
A88 and A113 are highly conserved among UIMs
of diﬀerent proteins (Figure 7A), and have been reported
to be important for UIM function (39). We, therefore,
examined the eﬀect of the A88S, A113S and the A88,113S
double mutation on the ubiquitination of RAP80C122.
Our data showed that the single mutations diminished
RAP80 multiubiquitination, while the double mutant
A88,113S caused a more pronounced decrease in
ubiquitination (Figure 8C). The results are in agreement
with the conclusion that UIM
RAP80 is required for
the multi-monoubiquitination of the amino terminus
of RAP80.
The UIMs of RAP80are critical forits effects on ERa
Next, we investigated the importance of the UIM
RAP80 on
the interaction of RAP80 with ERa. First, we examined
whether deletion of UIM
RAP80 had any eﬀect on the
subcellular localization of RAP80. Full-length FLAG–
RAP80 or FLAG–RAP80UIM1,2 was transiently
expressed in HeLa cells and their subcellular localization
examined by confocal microscopy. Figure S4 shows that
both FLAG–RAP80 and RAP80UIM1,2 were localized
to the nucleus.
To determine whether the UIMs play a role in
the interaction between RAP80 and ERa, HeLa cells
were co-transfected with pcDNA3.1–ERa–Myc-His and
pLXIN–3 FLAG–RAP80 expression plasmids encod-
ing either full-length RAP80 or several UIM deletion
mutants of RAP80. Co-immunoprecipitation analysis
showed that deletion of a single UIM or both UIMs did
not abrogate the interaction between RAP80 and ERa
(Figure S5).
To determine whether UIM
RAP80 was required for the
observed increase in the level of ERa protein by RAP80,
the eﬀects of RAP80 and RAP80UIM1,2 on the level of
ERa protein were compared. HeLa cells expressing pERa
only contained low levels of ERa protein. RAP80
signiﬁcantly enhanced ERa levels (Figure 9A), whereas
RAP80UIM1,2 only slightly increased the level of ERa
protein. Expression of HA–Ub caused a further increase
in the level of ERa protein. These data suggest that the
UIM
RAP80 is required for the increase in ERa protein level
induced by RAP80.
Previous studies have shown that ERa is degraded by
the ubiquitin–proteasome pathway (14,16,20). Since
UIMs have been implicated in ubiquitin binding and
in the modulation of ubiquitination (31), this raised the
question of whether RAP80 aﬀected ERa ubiquitination.
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Figure 7. RAP80 contains two functional ubiquitin-interacting motifs (UIMs). (A) Sequence comparison of the UIM1 and UIM2 of RAP80 with
those of epsin, hepatocyte growth factor-regulated tyrosine kinase substrate (HGS), the proteasome subunit PSMD4, the ubiquitin-speciﬁc peptidase
25 (USP25) and the consensus UIM sequence ( is a hydrophobic residue, e is a negatively charged residue and x is any amino acid). (B) UIM
RAP80
is able to bind ubiquitin. GST (lane 1) or a GST–UIM
RAP80 fusion protein (lane 2) was bound to glutathione-Sepharose 4B beads and then
incubated with 500ng of puriﬁed Ub2-7. After 1h incubation, beads were washed extensively and bound proteins solubilized. Bound proteins were
examined by western blot analysis with anti-Ub antibody (upper panel). The input for GST and GST–UIM
RAP80 was also shown (lower panel). (C)
UIM
RAP80 promotes monoubiquitination of EGFP–UIM
RAP80. pEGFP or pEGFP–UIM
RAP80 was transfected in HeLa cells with or without
pCMV–HA–Ub. Forty-eight hours later, the EGFP proteins were isolated with anti-GFP antibody. The proteins were separated with SDS-PAGE
and blotted with anti-HA (upper panel) and anti-GFP (lower panel) antibodies respectively. The IgGH and a non-speciﬁc band (NS) are indicated.
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Figure 8. Role of UIM
RAP80 in RAP80 ubiquitination. (A) HEK293
cells were transfected with pLXIN–3 FLAG–RAP80, pCMV–HA–Ub
as indicated. After 48h incubation, cells were treated with or without
25mM of MG132 for 4h before cell lysates were prepared.
Ubiquitinated proteins were isolated with anti-HA antibody and
examined by western blot analysis with anti-FLAG antibody. The
input RAP80 is shown in the lower panel. ‘ns’ indicates nonspeciﬁc
pull-down. (B) UIM
RAP80 promotes the ubiquitination of the amino
terminus of RAP80. HeLa cells were transfected with pLXIN–
3 FLAG–RAP80C78 or pLXIN–3 FLAG–RAP80122 with or
without pCMV–HA–Ub. Forty-eight hours later, FLAG–RAP80 was
isolated with FLAG M2 resin and examined by western blot analysis
with anti-HA and anti-FLAG antibodies. Non-speciﬁc staining of
IgG is indicated on the right. (C) HEK293 cells were transfected
with wild type or mutant pLXIN–3 FLAG–RAP80C122 and
pCMV–HA–Ub as indicated. Cells were treated and processed as
described under A.
A
B
C
Figure 9. Role of UIM
RAP80 on the interaction of RAP80 with ERa.
(A) UIM is required for the RAP80-induced increase in the level of
ERa protein. HeLa cells were transfected with pLXIN–3 FLAG–
RAP80, pERa and pCMV–HA–Ub. Forty-eight hours after transfec-
tion, cells were collected and protein cell lysates examined by western
blot analysis using anti-ERa, anti-FLAG M2 and anti-actin antibodies.
(B) Eﬀect of RAP80 on ERa polyubiquitination. HeLa cells were
transfected with pcDNA3–ERa–Myc-His, wild type pLXIN–
3 FLAG–RAP80 or FLAG–RAP80UIM1,2 and pCMV–HA–Ub
for 48h and treated with or without E2 for 24h. The cells were treated
with MG132 for 4h before collection and ERa proteins immunopre-
cipitated with an anti-ERa antibody. Western blot was performed with
an anti-HA or anti-ERa antibody to detect ERa ubiquitination and the
level of immunoprecipitated ERa, respectively. The level of FLAG–
RAP80 expression was determined with anti-FLAG M2 antibody
(lower panel). (C) UIM is required for the RAP80-induced increase in
ERa-mediated transactivation. MCF-7 cells were transfected with
diﬀerent amounts of pLXIN–3 FLAG–RAP80 or pLXIN–
3 FLAG–RAP80UIM1,2 and then treated with 100nM E2 or
ethanol for 24h. Cells were collected and assayed for luciferase
activity. The relative Luc activity was calculated and plotted. RAP80
expression was also detected with anti-FLAG M2 antibody (lower
panels).
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pcDNA3.1–ERa–Myc-His, pCMV–HA–ubiquitin and
pLXIN–3 FLAG–RAP80 or pLXIN–3 FLAG–
RAP80UIM1,2. Cells were treated with MG132 for
4h before protein extracts were prepared and protein
complexes immunoprecipitated with an anti-ERa anti-
body. The protein complexes were subsequently examined
by western blot analysis with anti-HA antibody to detect
ERa ubiquitination. In agreement with previous studies
(16), the presence of E2 enhanced polyubiquitination of
ERa (Figure 9B). Expression of RAP80 strongly inhibited
ERa polyubiquitination whereas RAP80UIM1,2 had
little eﬀect. These results suggest that the observed
increase in the level of ERa protein induced by RAP80
(Figure 6) may involve reduced polyubiquitination and
degradation of ERa. Reduced ERa protein levels were not
observed in the experiment described in Figure 10C and
may be due to the high expression of ERa induced by
pcDNA3.1–ERa–Myc-His. RAP80 did not aﬀect ERa
ubiquitination in the absence of E2 (Figure 9B) or in
the presence of tamoxifen (data not shown). The latter
is in agreement with the demonstration that interaction
of RAP80 with ERa is dependent on the presence of
an agonist.
We next examined whether UIM
RAP80 was required
for the modulation of ERa-mediated transcriptional
activation by RAP80. MCF-7 cells were co-transfected
with an ERE-Luc reporter plasmid and diﬀerent amounts
of pLXIN–3 FLAG–RAP80 or pLXIN–3 FLAG–
RAP80UIM1,2. In the absence of E2, both RAP80
and RAP80UIM1,2 had little eﬀect on Luc reporter
activity. Addition of E2 induced ERE-mediated transcrip-
tional activation by endogenous ERa; this activation was
enhanced by increased expression of RAP80. In contrast,
expression of the RAP80UIM1,2 mutant did not
augment ERa-mediated activation of the reporter
(Figure 9C). These results indicate that UIM
RAP80 is
critical for the modulation of ERa activity by RAP80.
DISCUSSION
In this study, we identify ERa as a new RAP80-interacting
protein. The interaction of RAP80 with nuclear receptors
is very selective since a number of receptors, including
ERb, PPARg, RORg and ERRa were unable to interact
with RAP80 either in the presence or absence of their
corresponding ligand. The interaction of RAP80 with
ERa is dependent on the presence of an ERa agonist,
as E2 and E3, promoted this interaction whereas the
antagonists ICI 182,780 and tamoxifen did not. Previous
studies have shown that binding of an agonist to the
ligand-binding pocket of ERa induces a conformational
change in the receptor. This involves a repositioning
of helix 12 that allows recruitment of co-activators
that subsequently mediate the transcriptional activation
of ERa target genes by ERa (3,6,40). Binding of an
antagonist induces a conformational change that results in
the recruitment of co-repressors rather than co-activators.
The dependency of the interaction of RAP80 with ERa on
agonist binding indicates that RAP80 interacts with the
transcriptionally active conformation of ERa.
The interaction between RAP80 and ERa was
conﬁrmed by mammalian two-hybrid analysis and
co-immunoprecipitation. In vitro pull-down analysis with
GST–RAP80 protein demonstrated that RAP80
interacted with full-length ERa,E R aN180 (containing
the DBD, hinge domain and LBD), and with ERaN248
(containing the hinge and LBD), but did not interact with
ERaC248 (containing the amino terminus, including
the DBD). These observations suggest that RAP80
and ERa physically interact with each other and indicate
that the amino terminus and DBD of ERa are not an
absolute necessity for this interaction. The requirement
of the LBD of ERa is in agreement with our observation
that the interaction is ligand dependent. Thus, ligand-
induced changes could unmask binding motifs in ERa
required for its interaction with RAP80.
To determine which domain in RAP80 is required for
its interaction with ERa, the eﬀect of various mutations
in RAP80 on this interaction was examined. Analysis
of a series of carboxyl-terminal deletions showed that
the zinc ﬁnger motifs are not required for the interaction
of RAP80 with ERa, but that the region between
aa 304 and 404 is essential. A number of transcriptional
mediators have been reported to interact with the LBD of
agonist-bound ERa through a sequence containing
an LXXLL consensus motif (3,41–43). RAP80 contains
two related sequences
296ILCQL and
625LLSFL. However,
deletion of
625LLSFL or mutation of
296ILCQL into
296ISCQL did not aﬀect the interaction of RAP80 with
ERa (not shown) suggesting that the interaction of
RAP80 with ERa involves a diﬀerent sequence.
In addition to the two zinc ﬁnger motifs, we identiﬁed
two putative UIMs at the amino terminus of RAP80
that exhibit high homology to the consensus UIM
eeexxxAxxxSxxexxxx (in which  is a hydrophobic
residue, e is a negatively charged residue and x is any
amino acid) (Figure 7A) (31,32). Several studies have
shown that UIMs often mediate the monoubiquitination
of proteins that contain these sequences (31,35,36,44). In
addition, UIMs have been reported to bind ubiquitin and
as such mediate intra- or intermolecular interactions by
interacting with ubiquitinated target proteins or proteins
containing a ubiquitin-like domain (30,31,35,37,45).
Analysis of the UIM
RAP80 demonstrated that RAP80
was able to bind polyubiquitin chains of diﬀerent lengths
and to varying degrees. In addition, UIM
RAP80 was able
to promote the monoubiquitination of a chimeric EGFP–
UIM
RAP80 protein and the amino terminus of RAP80
while no ubiquitination was observed when the UIM
RAP80
was deleted. In addition, point mutations in A88 and
A113, alanines that are highly conserved among UIMs,
greatly diminish ubiquitination of RAP80 (Figure 8C) in
agreement with previous observations (39). Although the
UIM
RAP80 contains two lysines, mutations of these lysines
had little eﬀect on RAP80 ubiquitination suggesting that
they are not substrates for monoubiquitination. This is
in agreement with reports indicating that lysines within
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the calculated size of ubiquitinated RAP80 (Figure 8A),
it was concluded that several lysines may become
monoubiquitinated. These observations support the con-
clusion that the UIM
RAP80 domain in RAP80 is functional
and able to guide monoubiquitination of RAP80 and,
in addition, is able to bind ubiquitin. We propose that
the UIM
RAP80 domain mediates a signal that is critical to
the function of RAP80.
Although the mechanisms of protein polyubiquitination
and their role in targeting proteins to proteasomes for
degradation has been intensively studied, the role of
(multi)monoubiquitination is not as well understood
(21,32,33,46). Monoubiquitination functions as a signal
that aﬀects the structure, activity or localization of the
target protein, thereby regulating a broad range of cellular
functions, including membrane protein traﬃcking, histone
function, transcriptional regulation, DNA repair and
replication. UIMs are required for the (multi)monoubi-
quitination of several proteins, such as epsin, Eps15, and
Eps15R, involved in receptor endocytosis (33,37,44,47).
These proteins play a critical role in the recruitment of
plasma membrane receptor proteins to clathrin-coated
pits and their internalization. Deletion or mutation in
these UIMs greatly impacts the internalization of mem-
brane receptors (48). A recent study provided evidence for
an intramolecular interaction between monoubiquitin and
the UIM in Eps15 and Hrs that prevents them to interact
with ubiquitinated membrane receptors, thereby aﬀecting
their traﬃcking (37). Since RAP80 is a nuclear protein, it
is likely not involved in membrane receptor endocytosis.
Monoubiquitination has been reported to be involved in
the regulation of several nuclear functions. For example,
monoubiquitination of histones does not target them for
degradation but has a role in the regulation of chromatin
remodeling and transcriptional regulation (49,50).
Monoubiquitination is also critical in DNA repair (51).
For example, the subunit S5a (Rpn10) of the 19S
proteosomal regulatory complex contains two UIMs
that interact with the ubiquitin-like (Ubl) domain of
RAD23B (HR23B), a protein that targets several proteins
to the proteasome, including the excision repair factor
XPC (30,32).
Monoubiquitination can also aﬀect the localization of
proteins (30,52). However, deletion of the UIMs in RAP80
does not aﬀect its nuclear localization. In addition, our
data show that the UIMs are not required for the
interaction of RAP80 with ERa, but are critical to the
eﬀects of RAP80 on ERa function. Since several
UIM-containing proteins have been reported to be
involved in ubiquitination or ubiquitin metabolism, we
examined whether RAP80 had any eﬀect on the ubiquiti-
nation of ERa. Our results demonstrate that increased
expression of RAP80 decreases the ubiquitination of ERa.
Although the UIMs were not required for the
interaction of RAP80 with ERa, deletion of UIM
RAP80
eliminates RAP80’s capacity to inhibit ERa ubiqui-
tination suggesting that the UIM
RAP80 is essential for the
eﬀect of RAP80 on ERa ubiquitination. What the
functions of ubiquitination of nuclear receptors are,
is still controversial and not yet completely understood
(21). Ubiquitination of ERa appears to have multiple
functions and can aﬀect ERa protein levels and turnover
and ERa-mediated transcriptional regulation at diﬀerent
steps in the ERa signaling pathway (14,16,53). One
function of ERa polyubiquitination is related to targeting
misfolded, unliganded ERa for degradation by the pro-
teasome system. This involves binding of the Hsc70-
interacting protein (CHIP) which, through its E3 ubiquitin
ligase activity, ubiquitinates ERa (16,54). Another role of
ERa ubiquitination relates to transcriptional regulation.
Several studies have shown that in the presence of
agonist, ERa is rapidly degraded by the proteasome
system (14,17,20). This turnover of ERa appears to be
important for eﬃcient ERa-dependent transcriptional
activation. Such a coupling between protein degradation
and transactivation might be an integral part of
nuclear receptor function. However, overexpression
of proteasome 26S subunit PSMC5 (SUG1) enhances the
ubiquitination of ERa in the presence of agonist
and inhibited transcriptional activation (55). In addition,
Fan et al. (56) reported that inhibition of proteasome
degradation by the proteasome inhibitor MG132
enhanced ERa-mediated transcriptional activation.
These studies suggest that there is a delicate balance
between level of ERa protein and transcriptional
activation.
Our results show that expression of RAP80 enhances
ERa-mediated transcriptional activation possibly by
causing an increase in ERa protein levels. The latter
may be related to the reduced ERa ubiquitination and
degradation. We show that the eﬀects of RAP80 on ERa
were dependent on UIM
RAP80, supporting our hypothesis
that this domain is critical to the function of RAP80. The
eﬀects of RAP80 on ERa are very similar to those recently
reported for MUC1 (8). MUC1 was shown to stabilize
ERa by inhibiting its ubiquitination (8). The carboxyl-
terminal subunit of MUC1 was shown to associate with
ERa complexes on estrogen-responsive promoters and to
stimulate ERa-mediated transcription. MUC1 mediates
this action by directly binding to the DBD of ERa in an
agonist-dependent manner. These diﬀerent ﬁndings indi-
cate the complex role of ubiquitination in the regulation of
ERa function (14,53).
In summary, in this study we identify ERa as a new
RAP80-interacting protein and show that this interaction
is dependent on ERa agonist binding. We demonstrate
that RAP80 is a UIM-containing protein with two
functional UIMs that are able to bind ubiquitin and
direct monoubiquitination. These UIMs are not required
for its interaction with ERa but appear necessary for the
decrease in ERa polyubiquitination and the increase in
ERa-mediated transcriptional activation induced by
RAP80. Our observations show that the UIM
RAP80 is
critical for the function of RAP80 and suggests that
RAP80 is an important modulator of ERa.
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